Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr. Lieu on the Predictive Value of BRAF V600E Mutations in mCRC

July 26th 2019

Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associate director for clinical research, at the University of Colorado Cancer Center, discusses the predictive value of BRAF V600E mutations in metastatic colorectal cancer (mCRC).

Dr. Fukuoka on Dosage for Regorafenib/Nivolumab Combo in Gastric Cancer and CRC

July 22nd 2019

Shota Fukuoka, MD, physician, National Cancer Center in Japan, discusses finding the recommended dosage of regorafenib plus nivolumab in patients with advanced gastric cancer or colorectal cancer.

Dr. Messersmith on the Rise of Molecular Testing in mCRC

July 19th 2019

Wells A. Messersmith, MD, co-leader of the Developmental Therapeutics Program, and director, GI Cancer Program, at the University of Colorado School of Medicine, discusses the rise of molecular testing in metastatic colorectal cancer (mCRC).

Regorafenib/Nivolumab Combo to Be Explored in Phase III MSS CRC Trial

July 18th 2019

The combination of regorafenib and nivolumab will be compared with regorafenib alone in a phase III trial of patients with microsatellite stable colorectal cancer, following encouraging phase Ib findings of the REGONIVO study.

NTRK Gene Fusions: Finding the "Golden Ticket" in Oncology

July 18th 2019

During an OncologyLive Peer Exchange, the panelists discuss some of the challenges they face when conducting molecular testing, including determining which patients to test, when to test, and how to test to ensure that no golden tickets, such as NTRK gene fusions, are missed. They also discuss the data surrounding TRK inhibitors and their experiences using these agents.

Triplet Targeted Therapy May Signal a New Standard in Metastatic CRC

July 17th 2019

Now, investigators are combining BRAF inhibitors with other targeted therapies in an effort to establish a new chemotherapy-free standard in patients with metastatic colorectal cancer.

Regorafenib vs TAS-102 Salvage Therapy

July 15th 2019

Promising Novel Agents and Treatments

July 15th 2019

Ongoing Treatment & Approach Advancements in mCRC

July 15th 2019

Combination Therapy Updates from ASCO 2019

July 15th 2019

Later-Line Therapy Innovations in MCRC

July 15th 2019

IMblaze370 Regimen in MSS Tumors

July 15th 2019

The Use of Regorafenib in Clinical Practice

July 15th 2019

ReDOS Study: Regorafenib Dose Optimization

July 15th 2019

Salvage Therapy Options for mCRC

July 15th 2019

Deciding Second-Line Treatment for mCRC

July 15th 2019

Frontline-Therapy Decision Factors for mCRC

July 15th 2019

Changing Realities in Treating mCRC

July 15th 2019

Future Directions in I/O Therapy for mCRC

July 10th 2019

Immunotherapy in CRC

July 10th 2019